

Extracellular Matrix-based Scaffolding Technologies for Periodontal

## and Peri-implant Soft Tissue Regeneration

Lorenzo Tavelli \*, DDS, Michael K. McGuire \*†‡, DDS, Giovanni Zucchelli \*§, DDS, PhD, Giulio Rasperini \*||, DDS, Stephen E. Feinberg ¶, DDS, MS, PhD Hom-Lay Wang \*, DDS, MS, PhD, William V. Giannobile \*#, DDS, MS, DMSc

\* Department of Periodontics & Oral Medicine, University of Michigan School of Dentistry, Ann Arbor, MI, USA

† Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy

‡ Private practice, Houston, TX, USA

‡ Department of Periodontics, University of Texas, Dental Branch Houston and Health Science Center at San Antonio, TX, USA

§ Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy

|| Department of Biomedical, Surgical and Dental Sciences, University of Milan, Foundation IRCCS Ca' Granda Policlinic, Milan, Italy

¶ Department of Oral and Maxillofacial Surgery, University of Michigan, Ann Arbor, MI, USA

# Department of Biomedical Engineering & Biointerfaces Institute, College of Engineering, University of Michigan, Ann Arbor, MI, USA

### Correspondence

William V. Giannobile, DDS, MS, DMSc

Najjar Professor of Dentistry and Chair, Department of Periodontics and Oral Medicine,  
University of Michigan, School of Dentistry

1011 North University Avenue

Ann Arbor, Michigan 48109-1078, USA.

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1002/JPER.19-0351](#).

This article is protected by copyright. All rights reserved.

E-mail address: [wgiannob@umich.edu](mailto:wgiannob@umich.edu)

**Word count (abstract):** 88 words

**Word count (main text):** 2,424 words

**Tables and figures:** 1 table and 4 figures

**Running title:** Extracellular matrix-based technologies for periodontal and peri-implant plastic surgery

**One sentence Summary:** This review highlights the current evidence on the use of matrix-based technologies for periodontal soft tissue repair

**Key words:** Acellular dermal graft, allogenic dermal matrix graft, collagen matrix, dental implant, extracellular matrices, gingival recessions, soft tissue augmentation, soft tissue volume, tissue engineering, tissue grafts

#### **Abstract**

The present article focuses on the properties and indications of scaffold-based extracellular matrix technologies as alternatives to autogenous soft tissue grafts for periodontal and peri-implant plastic surgical reconstruction. The different processing methods for the creation of cell-free constructs resulting in preservation of the extracellular matrices influence the characteristics and behavior of scaffolding biomaterials. The aim of this review is to discuss the properties, clinical application and limitations of extracellular matrix-based scaffold technologies in periodontal and peri-implant soft tissue augmentation when used as alternatives to autogenous soft tissue grafts.

## Scaffold constructs for soft tissue augmentation

Biomaterials have progressively gained popularity in periodontics due to their advantages compared to autogenous grafts, such as unrestricted availability, avoidance of a secondary surgical site, reduction of the surgical time, and patient's preference <sup>1</sup>. Indeed, the risk of developing moderate/severe post-operative swelling and pain increased at 3% and 4%, respectively for each minute of the surgical procedure <sup>2</sup>. Ideally, biomaterials should be characterized by certain properties, including biocompatibility, ease in surgical site adaptation and positioning, space maintenance, clot stabilization, tissue-integration, cell invasion/guidance, and promotion of cellular proliferation <sup>3</sup>. Based on their origin, scaffolds can be classified as allogenic, xenogeneic, alloplastic, and living constructs (when they include cells). This review aims to present the characteristics, clinical application, and limitations of extracellular matrix-based technologies in periodontal and peri-implant soft tissue augmentation.

### Natural and cadaveric scaffolds

#### *Decellularized Human Dermis*

Acellular dermal matrix (ADM) is a soft tissue graft obtained from human skin that has undergone a decellularization process <sup>4,5</sup>. Devoid of epithelium and cellular components, the preserved extracellular matrix (ECM) serves as a scaffold that promotes cellular migration and revascularization from the surrounding host tissues <sup>4-7</sup>.

First introduced for the treatment of burn wounds <sup>8</sup>, the ADM has been extensively used in several other indications, such as facial augmentation, dural replacement, breast reconstruction and esthetic plastic surgery <sup>4,9,10</sup>. In dentistry, ADM was firstly evaluated for increasing attached and/or keratinized gingivae <sup>11</sup>. However, the ADM clinical outcomes are inferior to the free gingival graft <sup>12,13</sup>. In particular, the ADM seems to be more prone to shrinkage, which may also explain the less

tissue thickness observed<sup>5,13</sup>. Histological data of sites treated with ADM show a “scar” tissue appearance<sup>6</sup>, although better esthetic and color match with the surrounding tissue has been described, when compared to a free gingival graft (FGG)<sup>5,6,13</sup>.

Currently, the ADM is more routinely used for root coverage procedures (Figure 1) and soft tissue augmentation at tooth or implant sites (Figure 2)<sup>14-19</sup>, particularly when avoiding a second surgical site and minimizing patient morbidity is the primary concern<sup>17,20,21</sup>. Although ADM is considered to be the graft substitute with the most similar outcomes to the connective tissue graft (CTG)<sup>22</sup>, a recent network meta-analysis evaluating the changes in root coverage outcomes over time showed that only CTG-treated sites had a trend towards the stability of the gingival margin among the other root coverage techniques<sup>19</sup>. Similarly, a 12-year follow-up study reported a significant relapse of the gingival margin in multiple gingival recession treated with ADM<sup>17</sup>. A possible mechanism may be that the ADM may not have the capability of inducing keratinization of the overlying epithelia<sup>5,7,13</sup>, which seems to be a positive predictor for the stability of the gingival margin<sup>17,19,23,24</sup>. It can be suggested that with the treatment of ADM, similar root coverage outcomes to CTG can be obtained in the presence of a distinct amount of keratinized tissue width at baseline ( $\geq 2$  mm<sup>17</sup>).

Various human-derived ADMs are currently available, including AlloDerm® \*\*, Puros Dermis® ††, and Allopatch ‡‡. Allopatch is derived from the human fascia lata from the American Association of Tissue Banks. This allograft is minimally processed, which may better preserve the biomechanical and biochemical properties of the allograft. It has been suggested that several properties should be considered when choosing the graft, including tissue origin, processing methods, cross linking and biomechanical properties<sup>25</sup>, and that the different procedures to obtain human allografts may influence scaffold characteristics, such as cell penetration and proliferations<sup>26,27</sup>. Kuo et al. compared ADM to Allopatch as scaffolds supporting cellular ingrowth in fabricating tissue engineered grafts (TEGs)<sup>27</sup>. They observed different properties between the allografts, suggesting that decellularization protocols can affect the scaffold biological and physical characteristics<sup>27</sup>.

Increased vascular invasion into the constructs were found for TEGs based on Allopatch compared to those including ADM. However, ADM-based TEGs showed more rapid cellular migration <sup>27</sup>.

### *Human amniotic membrane*

Human amniotic membrane (HAM) is the innermost fetal membrane lining the amniotic cavity (0.02-0.05 mm in thickness) which derives from healthy maternal donors during an elective Caesarian section <sup>28</sup>. All donors' serum samples are tested to ensure the absence of viruses and all serologic tests are also repeated 6 months later <sup>29</sup>. HAM undergoes a process of preparation and preservation, such as cryopreservation and glycerol preservation or lyophilization and gamma irradiation <sup>30</sup>, resulting in the elimination of the cellular component while preserving the matrix <sup>31,32</sup>. HAM is composed by a single epithelial layer, a thick basement membrane, and an avascular collagen layer <sup>28,30</sup>. The avascular stroma contains several growth factors, including epidermal growth factor (EGF), transforming growth factors alpha and beta (TGF- $\alpha$ , TGF- $\beta$ ), fibroblast growth factor-2 (FGF-2), and keratinocyte growth factor (KGF) <sup>29,33</sup>. These growth factors contribute to the anti-inflammatory, immunomodulatory, antimicrobial, antiviral, anti-scarring and analgesic properties <sup>28,30,34,35</sup>. In addition, it has been reported that HAM promotes epithelial wound healing, angiogenesis and ECM deposition <sup>28,30,34,35</sup>. Because of these properties, HAM has been used in several fields for the promotion of wound repair and regeneration <sup>30,36</sup>. In periodontics, it has been investigated for application in guided tissue regeneration <sup>36</sup> and in the treatment of gingival recessions <sup>28</sup>. In a randomized controlled study, it was confirmed that cryopreserved amniotic membrane was effective in enhancing cicatrization, wound healing and reducing pain in patients undergoing implant placement <sup>29</sup>. Disadvantages of this allograft includes difficulty in handling, rapid degradation and the lack of adherence in full-thickness burns where HAM acts as a temporary wound dressing <sup>37</sup>.

HAM is commercially available as BioXclude §§.

## *Xenogeneic collagen matrices*

### *Bilayered collagen matrix*

The Mucograft® III is a non-cross-linked, resorbable, porcine bilayered collagen matrix (CM) composed of collagen types I and III<sup>38,39</sup>. CM presents an occlusive compact layer of dense collagen, and smooth texture aiming at promoting cell adhesion and a porous structure facing the host tissue that enhances tissue integration and angiogenesis<sup>39-41</sup>. The compact layer, made from porcine peritoneum, acts as a barrier and provides stability, while the porous layer, obtained from the porcine skin, is designed for supporting blood clot stabilization and the promotion of cellular ingrowth<sup>39</sup>.

These properties demonstrate the potential clinical applications of the biomaterial in periodontal plastic surgical procedures, where CM has been used to increase keratinized tissue, cover single- and multiple- gingival recession(s) and augment soft tissue thickness<sup>41-43</sup>. Among its main advantages are the reduced surgical time and patient morbidity compared to autogenous soft tissue grafts<sup>41,42</sup>.

Clinical trials have shown that CM is able to increase the keratinized tissue width<sup>41,44</sup>, but some have questioned this potential due to it lacks cellular component that are needed for keratinized tissue formation<sup>45</sup>. Furthermore, the chance of root coverage procedures may also benefit from the addition of xenogeneic allografts<sup>46</sup>. However, a recent randomized clinical trial did not meet the non-inferiority endpoint of CM compared to the “gold standard” CTG in the treatment of multiple gingival recessions. These findings examined odds of achieving complete root coverage, although CM was related to a shortened surgical and recovery time<sup>42</sup>.

An excellent color match with the surrounding tissue was reported when CM was used in soft tissue augmentation<sup>39,40</sup>. This result may be due to the properties of CM that acts as a scaffold matrix,

accelerating migration of cells from adjacent tissues and at the same time as a protective dressing when left exposed<sup>41, 47</sup>.

Histological data has confirmed the good integration of CM in the host tissues without signs of adverse tissue reaction, or evidence of a significant inflammatory response<sup>38, 40, 48</sup>. Therefore, collagen matrices have also been proposed as scaffolds for supporting the proliferation of fibroblasts and keratinocytes in TEGs<sup>49, 50</sup>.

#### *Volume-stable collagen matrix*

A new porcine, porous, collagen matrix (Fibrogide®) has recently been introduced for soft tissue regeneration. This graft has also been called volume-stable collagen matrix (VCMX) since one of its main advantages is the ability to maintain a good volume stability<sup>51, 52</sup>. VCMX is made of collagen and undergoes a cross-linking providing volume stability and some elasticity at the same time<sup>51-53</sup>. VCMX has only one, porous, layer that promotes angiogenesis, ingrowth of fibroblasts, matrix biosynthesis, and tissue integration<sup>51, 52, 54</sup>. In contrast to CM that has been used also in an open environment, VCMX requires a submerged healing<sup>52, 55</sup>. Several preclinical and clinical studies investigating VMCX showed promising results in terms of volume gain, without any significant adverse reactions noted<sup>52, 55-57</sup> (Figure 3). Further studies with longer follow-up are needed to confirm these early findings of VCMX (especially compared to CTG) in increasing mucosal thickness at implant sites.

#### *Xenogeneic acellular dermal matrix*

Porcine-derived acellular dermal matrix (PADM: Mucoderm®) is a collagen matrix obtained from porcine dermis after a multi-step process aimed at removing all the antigenic components<sup>58, 59</sup>.

Therefore, PADM serves as a three-dimensional matrix, promoting the proliferation of fibroblasts and endothelial cells and supporting a fast revascularization of its structure<sup>58,60</sup>. The use of PADM has been suggested as a carrier for enamel matrix derivatives in the treatment of gingival recessions<sup>59</sup>, where histological evidence of periodontal regeneration was observed<sup>59</sup>. Figure 4 showed two clinical cases in which PADM was used for the treatment of soft tissue deficiencies at tooth and implant sites.

#### *Extracellular matrix*

The DynaMatrix® ## is a three-dimensional structure porcine-derived matrix from the submucosa of the small intestine in a cell-free procurement, while the natural composition of the matrix molecules is preserved<sup>61,62</sup>. The matrix provides a scaffold that promotes the repopulation of fibroblasts, blood vessels and epithelium from the adjacent tissues<sup>62</sup>. In vitro studies showed its favorable properties in stimulating cellular adhesion, differentiation and proliferation<sup>63,64</sup> as well as in facilitating angiogenesis<sup>65</sup>. These characteristics may explain the clinical outcomes of this matrix that was found to be effective and predictable in keratinized gingiva augmentation and in resembling the surrounding tissue<sup>62</sup>.

Although these extracellular matrix-based scaffolds have been proposed as an alternative to an autogenous graft, clinical considerations regarding their handling characteristics and stabilization compared to free gingival – and connective tissue graft is lacking in the literature. The clinical experience of the authors suggests that the use of these graft substitutes poses additional challenges for suturing the material on the recipient bed or for inserting it into a tunnel flap. It has been reported that one of the advantages of the VCMX compared to CM is the propriety of regains its initial volume within few minutes, due to its high elasticity<sup>52</sup>. Nevertheless, also VCMX seems to



be less resistant to compression than connective tissue graft which can be easily stabilized to the de-epithelialized papilla or inserted into the tunnel flap with sutures. In the future, there should be greater studies on the material handling characteristics to optimize placement during surgery.

### **Polymeric matrices**

Polymeric matrices have been widely used as biomaterials in tissue engineering for fabricating scaffolds and medical devices. Natural polymers can be derived from: i) proteins, including collagen, silk, gelatin and fibrin glue; ii) polysaccharides, such as hyaluronic acid and chitosan; and iii) polynucleotides<sup>66</sup>. Additionally, the manufacturing methods of natural and synthetic biomaterials include many processes, such as electrospinning, 3D printing or the use of CAD/CAM. Natural polymers were among the first biomaterials investigated in dental tissue engineering and, among their main advantages, a greater biocompatibility and interaction with host cells compared to synthetic matrices have been described<sup>66</sup>. Because of its properties of promoting wound healing, silk has been widely used as a scaffold in soft- and bone tissue engineering in combination with epidermal or mesenchymal stem cells or fibroblasts<sup>67,68</sup>. Collagen is the most abundant naturally-derived protein in the human body and it's the major protein of the ECM of the skin dermal layer<sup>67</sup>. Several collagen-based grafts have been proposed in wound healing and tissue engineering of skin, including ADM, cellular epidermis/dermis and bilayered skin equivalents<sup>67</sup>. The lack of biostability and frequent wound contracture are among the disadvantages of collagen-based scaffolds.<sup>67</sup> These limitations have been overcome by cross-linking the collagen matrices or by combining them with other ECM molecules<sup>67,69</sup>.

Synthetic materials have progressively become widely used in the biomedical field since they can be tailored for attaining different desired characteristics using various fabrication techniques<sup>66,67</sup>.

Compared to natural polymers, synthetic scaffolds are produced in large quantities and have a

longer shelf life. In addition, they show consistent properties, such as tensile strength, elastic modulus and degradation rate<sup>66</sup>. However, lack of cellular recognition, biocompatibility and biodegradability represent their main drawbacks that may limit its clinic application<sup>66</sup>. Given these shortcomings, synthetic biomaterials are usually used in combination with natural polymers<sup>67,70</sup>. Polycaprolactone (PCL), poly(lactic acid) or polylactic acid or polylactide (PLA), and poly(lactic-co-glycolic) acid (PLGA) are among the most used synthetic polymers in tissue engineering, specifically with bone regeneration<sup>66,71</sup>. PLGA is a versatile polymer that can be personalized to any shape and size while controlling its degradation time to match the rate of the tissue neogenesis or the desired drug release profile. This material has been used as a scaffold for tissue regeneration or as a drug delivery system, in particular as nano-/micro-particles of PLGA that are able to control the delivery of growth factors for tissue engineering applications<sup>72,73</sup>. Nevertheless, there is limited evidence available on the use of synthetic biomaterials for soft tissue reconstruction in humans. Table 1 summarizes the extracellular matrix- based scaffold used in periodontal and peri-implant soft tissue reconstruction.

### ***Concluding remarks***

Extracellular-based scaffolding technologies are effective in soft tissue augmentation at periodontal and peri-implant sites. Given that these materials are devoid of cells and usually cellular signaling molecules, they promote soft tissue volume, but not keratinized tissue neogenesis. Nevertheless, ECM scaffold constructs generally encourage the migration and the proliferation of fibroblasts and keratinocytes providing an excellent color match with the surrounding tissue. The reduced surgical time and morbidity compared to autogenous grafts is one of the main advantages of these materials as patient preferences indicate. The use of synthetic scaffolds made from polymeric biomaterials such as PCL, PLGA, and PLLA have shown good potential for combination drug delivery approaches, however as stand-alone technologies they do not promote new tissue formation or stimulate cellular

and vascular ingrowth critical for clinical success. Future research continues to examine combination biologic and/or cell-based ECM constructs for clinical application to improve treatment outcomes.

**Acknowledgments and Conflict of Interest Statement:** GZ and WVG have consulted with Geistlich Pharma. MKM has received direct research support from Geistlich Pharma and Tissue Tech. HLW has received research grants from BioHorizons Inc. and Snoasis as well as speaking for BioHorizon Inc. The other authors do not have any financial interests, either directly or indirectly, in the products or information associated with this manuscript. This paper was partially supported by the University of Michigan Periodontal Graduate Student Research Fund.

#### Footnotes

\*\* BioHorizons, Birmingham, AL, United States

†† Zimmer Dental, Carlsbad, CA

‡‡ Musculoskeletal Transplant Foundation, Edison, NJ, USA

§§ Snoasis Medical, LLC, Golden, CO, USA

||| Geistlich Pharma AG, Wolhusen, Switzerland

¶¶ Botiss Dental, Berlin, Germany

## Keystone Dental, Burlington, MA, USA

## REFERENCES

1. McGuire MK, Scheyer ET, Gwaltney C. Commentary: incorporating patient-reported outcomes in periodontal clinical trials. *J Periodontol* 2014;85:1313-1319.
2. Griffin TJ, Cheung WS, Zavras AI, Damoulis PD. Postoperative complications following gingival augmentation procedures. *J Periodontol* 2006;77:2070-2079.
3. Takata T, Wang HL, Miyauchi M. Attachment, proliferation and differentiation of periodontal ligament cells on various guided tissue regeneration membranes. *J Periodontol Res* 2001;36:322-327.
4. Bohac M, Danisovic L, Koller J, Dragunova J, Varga I. What happens to an acellular dermal matrix after implantation in the human body? A histological and electron microscopic study. *Eur J Histochem* 2018;62:2873.
5. Scarano A, Barros RR, Iezzi G, Piattelli A, Novaes AB, Jr. Acellular dermal matrix graft for gingival augmentation: a preliminary clinical, histologic, and ultrastructural evaluation. *J Periodontol* 2009;80:253-259.
6. Wei PC, Laurell L, Lingen MW, Geivelis M. Acellular dermal matrix allografts to achieve increased attached gingiva. Part 2. A histological comparative study. *J Periodontol* 2002;73:257-265.
7. Cummings LC, Kaldahl WB, Allen EP. Histologic evaluation of autogenous connective tissue and acellular dermal matrix grafts in humans. *J Periodontol* 2005;76:178-186.
8. Wainwright DJ. Use of an acellular allograft dermal matrix (AlloDerm) in the management of full-thickness burns. *Burns* 1995;21:243-248.
9. Castor SA, To WC, Papay FA. Lip augmentation with AlloDerm acellular allogenic dermal graft and fat autograft: A comparison with autologous fat injection alone. *Aesthetic Plast Surg* 1999;23:218-223.
10. Gryskiewicz JM. Alloderm lip augmentation. *Plast Reconstr Surg* 2000;106:953-954.
11. Shulman J. Clinical evaluation of an acellular dermal allograft for increasing the zone of attached gingiva. *Pract Periodontics Aesthet Dent* 1996;8:201-208.
12. Wei PC, Laurell L, Geivelis M, Lingen MW, Maddalozzo D. Acellular dermal matrix allografts to achieve increased attached gingiva. Part 1. A clinical study. *J Periodontol* 2000;71:1297-1305.
13. de Resende DRB, Greggi SLA, Siqueira AF, Benfatti CAM, Damante CA, Ragghianti Zangrando MS. Acellular dermal matrix allograft versus free gingival graft: a histological evaluation and split-mouth randomized clinical trial. *Clin Oral Investig* 2018.

14. Hutton CG, Johnson GK, Barwacz CA, Allareddy V, Avila-Ortiz G. Comparison of two different surgical approaches to increase peri-implant mucosal thickness: A randomized controlled clinical trial. *J Periodontol* 2018;89:807-814.
15. Wang HL, Romanos GE, Geurs NC, Sullivan A, Suarez-Lopez Del Amo F, Eber RM. Comparison of two differently processed acellular dermal matrix products for root coverage procedures: a prospective, randomized multicenter study. *J Periodontol* 2014;85:1693-1701.
16. Ozenci I, Ipci SD, Cakar G, Yilmaz S. Tunnel technique versus coronally advanced flap with acellular dermal matrix graft in the treatment of multiple gingival recessions. *J Clin Periodontol* 2015;42:1135-1142.
17. Tavelli L, Barootchi S, Di Gianfilippo R, et al. Acellular dermal matrix and coronally advanced flap or tunnel technique in the treatment of multiple adjacent gingival recessions. A 12-year follow-up from a randomized clinical trial. *J Clin Periodontol* 2019 Jun 26. doi: 10.1111/jcpe.13163. [Epub ahead of print]
18. Modaressi M, Wang HL. Tunneling procedure for root coverage using acellular dermal matrix: a case series. *Int J Periodontics Restorative Dent* 2009;29:395-403.
19. Tavelli L, Barootchi S, Cairo F, Rasperini G, Shedden K, Wang HL. The Effect of Time on Root Coverage Outcomes: A Network Meta-Analysis. *J Dent Res* 2019.
20. Henderson RD, Greenwell H, Drisko C, et al. Predictable multiple site root coverage using an acellular dermal matrix allograft. *J Periodontol* 2001;72:571-582.
21. Joly JC, Carvalho AM, da Silva RC, Ciotti DL, Cury PR. Root coverage in isolated gingival recessions using autograft versus allograft: a pilot study. *J Periodontol* 2007;78:1017-1022.
22. Chambrone L, Salinas Ortega MA, Sukekava F, et al. Root coverage procedures for treating localised and multiple recession-type defects. *Cochrane Database Syst Rev* 2018;10:CD007161.
23. Pini Prato GP, Franceschi D, Cortellini P, Chambrone L. Long-term evaluation (20 years) of the outcomes of subepithelial connective tissue graft plus coronally advanced flap in the treatment of maxillary single recession-type defects. *J Periodontol* 2018.
24. Pini Prato GP, Magnani C, Chambrone L. Long-term evaluation (20 years) of the outcomes of coronally advanced flap in the treatment of single recession-type defects. *J Periodontol* 2018;89:265-274.
25. Barber FA, Aziz-Jacobo J. Biomechanical testing of commercially available soft-tissue augmentation materials. *Arthroscopy* 2009;25:1233-1239.
26. Rodina AV, Tenchurin TK, Saprykin VP, et al. Proliferative and Differentiation Potential of Multipotent Mesenchymal Stem Cells Cultured on Biocompatible Polymer Scaffolds with Various Physicochemical Characteristics. *Bull Exp Biol Med* 2017;162:488-495.

27. Kuo S, Kim HM, Wang Z, et al. Comparison of two decellularized dermal equivalents. *J Tissue Eng Regen Med* 2018;12:983-990.
28. Jain A, Jaiswal GR, Kumathalli K, Kumar R, Singh A, Sarwan A. Comparative Evaluation of Platelet Rich Fibrin and Dehydrated Amniotic Membrane for the Treatment of Gingival Recession- A Clinical Study. *J Clin Diagn Res* 2017;11:ZC24-ZC28.
29. Velez I, Parker WB, Siegel MA, Hernandez M. Cryopreserved amniotic membrane for modulation of periodontal soft tissue healing: a pilot study. *J Periodontol* 2010;81:1797-1804.
30. Kesting MR, Wolff KD, Nobis CP, Rohleder NH. Amniotic membrane in oral and maxillofacial surgery. *Oral Maxillofac Surg* 2014;18:153-164.
31. Bhatia M, Pereira M, Rana H, et al. The Mechanism of Cell Interaction and Response on Decellularized Human Amniotic Membrane: Implications in Wound Healing. *Wounds* 2007;19:207-217.
32. Tseng SC, Espana EM, Kawakita T, et al. How does amniotic membrane work? *Ocul Surf* 2004;2:177-187.
33. Hodde J. Naturally occurring scaffolds for soft tissue repair and regeneration. *Tissue Eng* 2002;8:295-308.
34. Kim TG, Do Ki K, Lee MK, So JW, Chung SK, Kang J. Comparison of cytokine expression and ultrastructural alterations in fresh-frozen and dried electron beam-irradiated human amniotic membrane and chorion. *Cell Tissue Bank* 2019;20:163-172.
35. Russo A, Bonci P, Bonci P. The effects of different preservation processes on the total protein and growth factor content in a new biological product developed from human amniotic membrane. *Cell Tissue Bank* 2012;13:353-361.
36. Kiany F, Moloudi F. Amnion membrane as a novel barrier in the treatment of intrabony defects: a controlled clinical trial. *Int J Oral Maxillofac Implants* 2015;30:639-647.
37. Haddad AG, Giatsidis G, Orgill DP, Halvorson EG. Skin Substitutes and Bioscaffolds: Temporary and Permanent Coverage. *Clin Plast Surg* 2017;44:627-634.
38. Ghanaati S, Schlee M, Webber MJ, et al. Evaluation of the tissue reaction to a new bilayered collagen matrix in vivo and its translation to the clinic. *Biomed Mater* 2011;6:015010.
39. Nevins M, Nevins ML, Kim SW, Schupbach P, Kim DM. The use of mucograft collagen matrix to augment the zone of keratinized tissue around teeth: a pilot study. *Int J Periodontics Restorative Dent* 2011;31:367-373.
40. Jung RE, Hurzeler MB, Thoma DS, Khraisat A, Hammerle CH. Local tolerance and efficiency of two prototype collagen matrices to increase the width of keratinized tissue. *J Clin Periodontol* 2011;38:173-179.

41. Sanz M, Lorenzo R, Aranda JJ, Martin C, Orsini M. Clinical evaluation of a new collagen matrix (Mucograft prototype) to enhance the width of keratinized tissue in patients with fixed prosthetic restorations: a randomized prospective clinical trial. *J Clin Periodontol* 2009;36:868-876.
42. Tonetti MS, Cortellini P, Pellegrini G, et al. Xenogenic collagen matrix or autologous connective tissue graft as adjunct to coronally advanced flaps for coverage of multiple adjacent gingival recession: Randomized trial assessing non-inferiority in root coverage and superiority in oral health-related quality of life. *J Clin Periodontol* 2018;45:78-88.
43. Cairo F, Barbato L, Tonelli P, Batalocco G, Pagavino G, Nieri M. Xenogeneic collagen matrix versus connective tissue graft for buccal soft tissue augmentation at implant site. A randomized, controlled clinical trial. *J Clin Periodontol* 2017;44:769-776.
44. Lorenzo R, Garcia V, Orsini M, Martin C, Sanz M. Clinical efficacy of a xenogeneic collagen matrix in augmenting keratinized mucosa around implants: a randomized controlled prospective clinical trial. *Clin Oral Implants Res* 2012;23:316-324.
45. Yu SH, Tseng SC, Wang HL. Classification of Soft Tissue Grafting Materials Based on Biologic Principles. *Int J Periodontics Restorative Dent* 2018;38:849-854.
46. Jepsen K, Jepsen S, Zucchelli G, et al. Treatment of gingival recession defects with a coronally advanced flap and a xenogeneic collagen matrix: a multicenter randomized clinical trial. *J Clin Periodontol* 2013;40:82-89.
47. Vignoletti F, Nunez J, de Sanctis F, Lopez M, Caffesse R, Sanz M. Healing of a xenogeneic collagen matrix for keratinized tissue augmentation. *Clin Oral Implants Res* 2015;26:545-552.
48. Vignoletti F, Nunez J, Discepoli N, et al. Clinical and histological healing of a new collagen matrix in combination with the coronally advanced flap for the treatment of Miller class-I recession defects: an experimental study in the minipig. *J Clin Periodontol* 2011;38:847-855.
49. McGuire MK, Scheyer ET, Nunn ME, Lavin PT. A pilot study to evaluate a tissue-engineered bilayered cell therapy as an alternative to tissue from the palate. *J Periodontol* 2008;79:1847-1856.
50. Milinkovic I, Aleksic Z, Jankovic S, et al. Clinical application of autologous fibroblast cell culture in gingival recession treatment. *J Periodontol Res* 2015;50:363-370.
51. Thoma DS, Nanni N, Benic GI, Weber FE, Hammerle CH, Jung RE. Effect of platelet-derived growth factor-BB on tissue integration of cross-linked and non-cross-linked collagen matrices in a rat ectopic model. *Clin Oral Implants Res* 2015;26:263-270.
52. Thoma DS, Zeltner M, Hilbe M, Hammerle CH, Husler J, Jung RE. Randomized controlled clinical study evaluating effectiveness and safety of a volume-stable collagen matrix compared to autogenous connective tissue grafts for soft tissue augmentation at implant sites. *J Clin Periodontol* 2016;43:874-885.

53. Agis H, Collins A, Taut AD, et al. Cell population kinetics of collagen scaffolds in ex vivo oral wound repair. *PLoS One* 2014;9:e112680.
54. Thoma DS, Villar CC, Cochran DL, Hammerle CH, Jung RE. Tissue integration of collagen-based matrices: an experimental study in mice. *Clin Oral Implants Res* 2012;23:1333-1339.
55. Thoma DS, Naenni N, Benic GI, Hammerle CH, Jung RE. Soft tissue volume augmentation at dental implant sites using a volume stable three-dimensional collagen matrix - histological outcomes of a preclinical study. *J Clin Periodontol* 2017;44:185-194.
56. Zeltner M, Jung RE, Hammerle CH, Husler J, Thoma DS. Randomized controlled clinical study comparing a volume-stable collagen matrix to autogenous connective tissue grafts for soft tissue augmentation at implant sites: linear volumetric soft tissue changes up to 3 months. *J Clin Periodontol* 2017;44:446-453.
57. Ferrantino L, Bosshardt D, Nevins M, Santoro G, Simion M, Kim D. Tissue Integration of a Volume-Stable Collagen Matrix in an Experimental Soft Tissue Augmentation Model. *Int J Periodontics Restorative Dent* 2016;36:807-815.
58. Pabst AM, Happe A, Callaway A, et al. In vitro and in vivo characterization of porcine acellular dermal matrix for gingival augmentation procedures. *J Periodontol Res* 2014;49:371-381.
59. Shirakata Y, Sculean A, Shinohara Y, et al. Healing of localized gingival recessions treated with a coronally advanced flap alone or combined with an enamel matrix derivative and a porcine acellular dermal matrix: a preclinical study. *Clin Oral Investig* 2016;20:1791-1800.
60. Rothamel D, Benner M, Fienitz T, et al. Biodegradation pattern and tissue integration of native and cross-linked porcine collagen soft tissue augmentation matrices - an experimental study in the rat. *Head Face Med* 2014;10:10.
61. Hodde J, Janis A, Ernst D, Zopf D, Sherman D, Johnson C. Effects of sterilization on an extracellular matrix scaffold: part I. Composition and matrix architecture. *J Mater Sci Mater Med* 2007;18:537-543.
62. Nevins M, Nevins ML, Camelo M, Camelo JM, Schupbach P, Kim DM. The clinical efficacy of DynaMatrix extracellular membrane in augmenting keratinized tissue. *Int J Periodontics Restorative Dent* 2010;30:151-161.
63. Lindberg K, Badylak SF. Porcine small intestinal submucosa (SIS): a bioscaffold supporting in vitro primary human epidermal cell differentiation and synthesis of basement membrane proteins. *Burns* 2001;27:254-266.
64. Badylak SF, Park K, Peppas N, McCabe G, Yoder M. Marrow-derived cells populate scaffolds composed of xenogeneic extracellular matrix. *Exp Hematol* 2001;29:1310-1318.
65. Nihsen ES, Johnson CE, Hiles MC. Bioactivity of small intestinal submucosa and oxidized regenerated cellulose/collagen. *Adv Skin Wound Care* 2008;21:479-486.



66. Dhandayuthapani B, Yoshida Y, Maekawa T, Kumar DS. Polymeric Scaffolds in Tissue Engineering Application: A Review. *International Journal of Polymer Science* 2011;2011.
67. Bhardwaj N, Chouhan D, Mandal BB. Tissue Engineered Skin and Wound Healing: Current Strategies and Future Directions. *Curr Pharm Des* 2017;23:3455-3482.
68. Xie SY, Peng LH, Shan YH, Niu J, Xiong J, Gao JQ. Adult Stem Cells Seeded on Electrospinning Silk Fibroin Nanofibrous Scaffold Enhance Wound Repair and Regeneration. *J Nanosci Nanotechnol* 2016;16:5498-5505.
69. Park SN, Lee HJ, Lee KH, Suh H. Biological characterization of EDC-crosslinked collagen-hyaluronic acid matrix in dermal tissue restoration. *Biomaterials* 2003;24:1631-1641.
70. Ciardelli G, Chiono V, Vozzi G, et al. Blends of poly-(epsilon-caprolactone) and polysaccharides in tissue engineering applications. *Biomacromolecules* 2005;6:1961-1976.
71. Kim RY, Fasi AC, Feinberg SE. Soft tissue engineering in craniomaxillofacial surgery. *Ann Maxillofac Surg* 2014;4:4-8.
72. Wei G, Jin Q, Giannobile WV, Ma PX. Nano-fibrous scaffold for controlled delivery of recombinant human PDGF-BB. *J Control Release* 2006;112:103-110.
73. Wei G, Jin Q, Giannobile WV, Ma PX. The enhancement of osteogenesis by nano-fibrous scaffolds incorporating rhBMP-7 nanospheres. *Biomaterials* 2007;28:2087-2096.
74. Ebell MH, Siwek J, Weiss BD, et al. Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. *Am Fam Physician* 2004;69:548-556.


## Figures Legend

**Figure 1.** A-F) Coronally advanced flap and acellular dermal matrix for the treatment of an isolated gingival recession. A) Pre-operative gingival recession on the left maxillary canine; B) Flap design and elevation; C) Acellular dermal matrix adapted and sutured over the root; D) Flap coronally advanced and sutured; E) 6-months result; F) The complete root coverage is maintained also at the 10-year recall. G-L) Tunnel technique and acellular dermal matrix used for the treatment of multiple adjacent gingival recessions. G) Clinical scenario at baseline; H) tunnel flap is performed; I) acellular dermal matrix is inserted in the flap; J) the flap is sutured together with the graft material in a coronally advanced position; K) 2-week post-op; L) 6-months result showing the complete root coverage of the recession defects (Adapted with permission from<sup>17</sup>).




**Figure 2.** Acellular dermal matrix used for soft tissue augmentation in a maxillary dental implant

lacking buccal bone. A) Clinical scenario before bone augmentation; B) 6-months after guided bone regeneration; C-D) soft tissue augmentation by using an acellular dermal matrix; E) flap closure; F) 5-years recall showing the stability of the obtained soft tissue volume.



**Figure 3.** Volume-stable collagen matrix around teeth used for root coverage purposes. A) Gingival recession defect on a maxillary canine; B) A split-full-split flap limited to the canine was performed; C) After the de-epithelialization of the anatomical papillae, a volume-stable collagen matrix was applied on the root surface and sutured to the de-epithelialized papillae; D) The flap was coronally advanced and sutured; E) 1-year outcomes.



**Figure 4.** Xenogeneic acellular dermal matrix used for the treatment of multiple adjacent gingival recessions (A-E) and for soft tissue augmentation at a single implant site (F-K). A) Multiple adjacent maxillary gingival recessions; B-C) After the split-full-split envelope flap preparation, a xenogeneic acellular dermal matrix was inserted and stabilized over the roots; D) Flap closure; E) 1-year outcomes; F) Dental implant presenting with inadequate soft tissue thickness and poor esthetics; G-H) xenogeneic acellular dermal matrix sutured around the implant; I) Flap closure; J-K) 1-year outcomes showing improved peri-implant soft tissue thickness, contour and esthetics.



**Table 1.** Summary of the extracellular matrix- based scaffolds used in periodontal and peri-implant soft tissue reconstruction

Scaffold	Origin	Main advantages	Primary indications	Secondary indications	Level of Evidence (SORT)	Reference(s)
Decellularized Human Dermis	Human acellular dermis	<ul style="list-style-type: none"> <li>Promotes cellular migration and revascularization from the host tissues</li> <li>Minimal patient morbidity</li> </ul>	<ul style="list-style-type: none"> <li>Root coverage</li> <li>Increasing tissue thickness</li> </ul>	<ul style="list-style-type: none"> <li>Increasing keratinized tissue in combination with apically positioned flap</li> </ul>	A	Scarano et al. 2009, Wang et al. 2014, Hutton et al. 2018 <sup>5, 14, 15</sup>
Human amniotic membrane	Innermost fetal membrane lining the amniotic cavity	<ul style="list-style-type: none"> <li>Contains several growth factors</li> <li>Anti-inflammatory, immunomodulatory, antimicrobial, antiviral, anti-scarring and analgesic properties</li> <li>Promotes epithelial wound healing, angiogenesis and extracellular matrix deposition</li> </ul>	<ul style="list-style-type: none"> <li>Root coverage</li> </ul>	<ul style="list-style-type: none"> <li>Adjunctive to surgery for enhancing wound healing</li> </ul>	C	Velez et al. 2010, Kiany et al. 2015, Jain et al. 2017 <sup>28, 29, 36</sup>

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1002/JPER.19-0351](https://doi.org/10.1002/JPER.19-0351).

This article is protected by copyright. All rights reserved.

Bilayer collagen matrix	Porcine	<ul style="list-style-type: none"> <li>• One layer promotes cell adhesion, and enhances tissue integration and angiogenesis, while the other acts as a barrier and provides stability</li> <li>• Excellent color match with the adjacent tissue</li> <li>• Lower morbidity than autogenous grafts</li> </ul>	<ul style="list-style-type: none"> <li>• Root coverage</li> <li>• Increasing tissue thickness</li> </ul>	<ul style="list-style-type: none"> <li>• Increasing keratinized tissue in combination with apically positioned flap</li> </ul>	A	Sanz et al. 2009, Lorenzo et al. 2012, Cairo et al. 2017, Tonetti et al. 2018 <sup>41-44</sup>
Volume-stable collagen matrix	Porcine	<ul style="list-style-type: none"> <li>• Maintenance of a good volume stability</li> <li>• Promotes angiogenesis and ingrowth of fibroblasts</li> </ul>	<ul style="list-style-type: none"> <li>• Root coverage</li> <li>• Increasing tissue thickness</li> </ul>	<ul style="list-style-type: none"> <li>• Increasing keratinized tissue in combination with apically positioned flap</li> </ul>	B	Thoma et al. 2016, 2017, Zeltner et al. 2017 <sup>52, 55, 56</sup>
Xenogenic acellular dermal matrix	Porcine dermis	<ul style="list-style-type: none"> <li>• It promotes the proliferations of fibroblasts and endothelial cells</li> </ul>	<ul style="list-style-type: none"> <li>• Root coverage</li> <li>• Increasing tissue thickness</li> </ul>		B	Shirikata et al. 2016 <sup>59</sup>
Extracellular Matrix (as stand-alone technology)	Porcine small intestine submucosa	<ul style="list-style-type: none"> <li>• Promotes the repopulation of fibroblasts, blood vessels and epithelium from the adjacent tissues</li> <li>• Stimulates cellular adhesion, differentiation</li> </ul>	<ul style="list-style-type: none"> <li>• Increasing keratinized tissue in combination with apically positioned flap</li> </ul>		C	Nevins et al. 2010 <sup>62</sup>

		and proliferation				
--	--	-------------------	--	--	--	--

**Legend.** SORT: Strength-of-Recommendation Taxonomy. SORT A: consistent, good-quality patient-oriented evidence; SORT B: inconsistent or limited-quality patient-oriented evidence; SORT-C: consensus, disease-oriented evidence, usual practice, expert opinion or case series for studies of diagnosis, treatment, prevention, or screening <sup>74</sup>